Daré Bioscience (DARE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Supplement details engagement of Okapi Partners LLC to assist with proxy solicitation for the 2026 annual meeting scheduled for June 11, 2026.
Okapi will provide strategic advice and may solicit proxies through various communication methods.
Okapi's fee is $15,000 plus additional fees and expenses, with indemnification for certain liabilities.
The company will bear all costs of proxy solicitation, including reimbursement to intermediaries forwarding materials.
Voting matters and shareholder proposals
Proxies are being solicited for the 2026 annual meeting and any adjournments or postponements.
Board of directors and corporate governance
Directors and employees may participate in proxy solicitation without additional compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Daré Bioscience
- Imminent launches and clinical milestones position the pipeline for strong near-term growth.DARE
TD Cowen 46th Annual Health Care Conference15 Jun 2026 - All eight proposals, including director elections and stock plan amendments, were approved.DARE
AGM 202611 Jun 2026 - Annual meeting on June 11, 2026, with virtual voting and emphasis on shareholder participation.DARE
Proxy filing1 Jun 2026 - First product revenue expected June 2026, but ongoing viability depends on new capital.DARE
Q1 202620 May 2026 - Annual meeting covers director elections, compensation, auditor, and share issuance proposals.DARE
Proxy filing28 Apr 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and key capital proposals.DARE
Proxy filing28 Apr 2026 - Proxy covers director elections, auditor ratification, compensation, and key capital structure proposals.DARE
Proxy filing17 Apr 2026 - DARE to PLAY launched nationwide; new product revenues and pipeline milestones expected in 2026-2027.DARE
Q4 202527 Mar 2026 - Q2 net income hit $12.9M on royalty sale, but liquidity and future losses remain concerns.DARE
Q2 20241 Feb 2026